Aminoglycoside

PreclinicalSmall molecule

Pfizer

Aminoglycoside is one of 68 small molecule programs targeting Kidney Injury. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney InjuryActive, not recruiting

Infective EndocarditisActive, not recruiting

Acute Kidney InjuryActive, not recruiting

Kidney InjuryPreclinical

Active, not recruiting

Infective EndocarditisPreclinical

Active, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

92 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

1 2

Inderal

WWyeth-Lederle Vaccines

Approved

1 3

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

2 4

Oraverse

LLife Extension Foundation Inc.

Phase 3

1 5

Northera

Lundbeck

Phase 2

1 6

Desferal

Jazz Pharmaceuticals

Phase 2

1 7

Lamisil

Novartis

Phase 2

1 8

Pitressin

AAultman Health Foundation

Phase 2

1 9

Arginine Vasopressin

SStanford University

Phase 3

1 10

Jardiance

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Cystic Fibrosis

NCT05548283

Clinical

Trials by Indication[1]

Sepsis1 trial

Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02424734·11 enrolled

Acute Kidney Injury1 trial

Risk Factors and Machine Learning Model for Aminoglycines Related Acute Kidney Injury

Completed·QQianfoshan Hospital··NCT05533593·8,000 enrolled

Kidney Injury1 trial

Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children

Completed·VVirginia Commonwealth University··NCT00308906·166 enrolled

Infective Endocarditis1 trial

Prosthetic Valve Sweing Ring Injection by Antiboitics Can Affect the Rate of Postoperative Infective Endocarditis?

Unknown status·—··NCT05455788·300 enrolled

Cystic Fibrosis1 trial

Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)

Recruiting·CChris Goss·Approved·NCT05548283·730 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Aminoglycoside. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aminoglycoside compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aminoglycoside. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Aminoglycoside

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Sepsis1 trial

Acute Kidney Injury1 trial

Kidney Injury1 trial

Infective Endocarditis1 trial

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News